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1. Introduction
Perianal and anal canal malignancies are uncommon. The anal canal is a small area, rather
complex for the presence of different histological features and for the lymphatic spread [1].
In the IUCC, American Joint Committee on Cancer (AJCC) and World Health Organization
(WHO) staging systems the anal canal is described as the last part of the gastrointestinal tract
extending from the anal ring at the level of the puborectalis muscle (where the rectum enters
the pelvic floor), to the perianal tissue that is the junction of the hair- bearing skin and the non-
keratinizing squamous epithelium of the distal anal canal.
As cited tumors of the anal canal can present different histological features. These guidelines
refer to squamous cell carcinoma (including the so called cloacogenic variant) which consti‐
tutes 80% of all lesions of this area and derives from transitional and squamous cell epithelium.
In some pathology literature squamous cell carcinoma of the anal canal is also described
according to additional histopathologic feature such as keratinization, presence of mucin and
abundance of basement mebrane-like material.
Less common are adenocarcinoma and mucinous adenocarcinoma of the anal glands or of fistula
tracts that must be distinguished from very low rectal cancers. Other uncommon neoplasms of
the anal canal include small  cell  carcinoma, carcinoid and other neuroendocrine tumors,
malignant melanoma, squamous cell papilloma, papillary hidradenoma, keratoacanthoma,
mesenchymal and neurogenic tumors, lymphoma, leiomyosarcoma, and secondary tumors.
Tumors originating from the anal margin should be staged as skin cancer: they can be
squamous cell cancer, basal cell cancer, Bowen’s or Paget’s disease.
This is an important distinction as skin cancers rarely involve lymph nodes or lead to distant
metastases [2-4].
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2. Incidence
Anal cancer remains a rare disease but its incidence is increasing [5], mainly in association with
human papillomaviruses (HPV) infection. An estimated 5820 new cases (2140 men and 3680
women) were estimated to occur in the United States in 2011, accounting for approximately
2.1% of digestive system cancers. It has been estimated that 770 deaths due to anal cancer will
occurr in U.S. alone in 2011 [6].
In western Europe the average annual incidence of anal carcinoma is 1 to 3 cases per 100,000
with a female prevalence (two to four times that of men [7]) and a highest incidence during
the sixth and seventh decades of life [8]. The annual incidence incidence can be up to 35 per
100,000 in men who practice anal-receptive sexual intercourse, and those who are human
immunodeficiency virus (HIV)-positive have twice the risk of those who are not [7].
In particular, squamous cell carcinoma (the other names, epidermoid or spinocellular, are no
longer used) is the most common histological type of anal carcinoma and constitutes up to the
80% of all malignant anal tumours [9].
3. Etiology
Chromosome 11 deletions (11q22) or the short arm of chromosome 3 (3p22), environmental
factors such as cigarette smoking, sexual orientation and a high number of sexual partners,
anoreceptive intercourse, male homosexuality, viral infections of the anogenital area (human
papillomavirus (HPV) virus type 16 and 18) and immunodeficiency, are all considered as
causative factors of anal cancer [8, 10-11].
The introduction of antiretroviral drugs have improved the life expectancy of HIV- positive
patients. This has contributed to increasing the incidence of anal cancer in this population.
HPV infection (type 16 in about 87% of cases [12]) and anogenital warts are closely associated
with anal cancer. Anal canal lesions are more often HPV positive than perianal lesions. Ninety-
five percent of anal canal cancer in women and 83% in men is HPV- positive while cancer
located at the anal margin are HPV- positive in only 80% of women and 28% of men [12].
Because of this high association with anal cancer HPV is considered to be the most important
causative factor much like in cases of cervical cancer [13-16].
In particular, HPV is involved in the pathogenesis of anal intraepithelial neoplasia (AIN) which
progresses from dysplasia to invasive cancer. HPV type 16 seems to be associated with a higher
risk of malignant transformation [17].
Other viral infections such as herpes simplex virus (HSV) have been studied but are considered
to play only a marginal role in disease progression.
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After solid organ transplant, patients receive chronic immunosuppressive therapy, so they are
exposed to higher risk of various squamous cell carcinoma, such as of the anal canal [11].
Moreover, the use of corticosteroids can increase the risk of developing anal cancer [18].
Several studies made a connection between cigarette smoking and risk of developing anal
cancer, and this risk diminished after smoking cessation [19].
4. Clinical manifestations
Macroscopically the squamous anal cancer appears as a small ulceration or fissure, exophytic,
with indurated margins and irregular thickening [20]. Sometimes large lesions are observed.
Symptoms are rectal bleeding, rectal pain, tenesmus or mass sensation, but about 20% of
patients are asymptomatic at the time of diagnosis [6].
5. Treatment
Prior to the mid-1980s, the treatment of choice for anal cancer was abdominoperineal resection
(APR). The 5-year survival rate after APR for anal cancer was 40-70%, with worse outcomes
for those with larger tumors and nodal metastases. In the 1920s and 1930s inguinal node
dissection was included in the surgical management of these patients, and it was generally
reserved for those patients with clinically enlarged (though not necessarily involved) inguinal
nodes [21]. By the 1950s it had became clear that the morbidity associated with lymph node
dissection was much greater than any survival benefit, so the procedure was gradually
abandoned [22]. In 1974 Nigro proposed a multimodality treatment combining radiation and
chemotherapy which has since then become the standard treatment with surgery reserved for
salvage treatment following local failure [23]. Local control rates of 60-90% over all stages are
achievable, with sphincter preservation in about 65% of cases. The prognosis after combined
radiochemotherapy for anal cancer may be influenced by several factors: high tumor stage and
regional nodal involvement; tumor site in the anal canal; inguinal lymph node involvement
in anal canal carcinoma. Synchronous inguinal metastases occur in 10-25% of patients [24] and
constitute an independent prognostic factor for local failure and overall mortality according
to a multivariate analysis in a phase 3 EORTC trial [25]. Metachronous metastases have been
reported in 5-25% of patients [10].
Adverse effects of chemoradiation therapy can be mucositis, diarrhea, skin desquamation and
erytema, mielosuppression, ulcers, fistulae, necrosis, and stenosis [19]. Surgery treatment is
reserved for salvage theraphy, in subjects with persistent or recurrent disease [19, 26-28]. The
elective treatment of metastatic disease (often hepatic nodules), is chemotherapy; therapeutic
plans include cisplatin and 5-FU, carboplatin, doxorubicin and semustine [29-32].
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6. Diagnosis
Clinical workup in the staging of anal cancer comprises digital rectal examination, anoscopy
with biopsy of suspicious lesions, palpation of inguinal lymph nodes, tumor marker assay,
chest X-ray, rigid proctoscopy, total colonoscopy, rectal endosonography, contrast-enhanced
diagnostic computed tomography (CT) and/or magnetic resonance imaging (MRI).
In effect, physical examination, biopsy of the tumor and endorectal ultrasonography can help
in determining the tumor depth and the invasion of perirectal limph nodes; instead, palpation
of the groin, CT and MRI can give important information about inguinal and iliac lymph node
involvement and the evidence of distant visceral metastasis. In recent years, fluorodeoxyglu‐
cose-positron emission tomography (18F-FDG-PET/CT) has rapidly gained a expanding role
in oncology, with mounting evidence for its effectiveness in the staging and management of
various types of tumors.
7. PET-CT and tumor
2-deoxy-2[F-18]fluoro-D-glucose (FDG) Positron Emission Tomography (PET) scan is a
medical examination currently approved and used in the staging work-up of primary cancers
of several sites, such as lung, head and neck, oesophagus, breast, colorectum, melanoma, the
Hodgkin's disease and non-Hodgkin's limphomas.
High rates of glycolysis are found in many malignant tumor cells and high uptake of FDG is
usually associated with a high expression of glucose transporters. Many tumors are avid of
FDG and PET/CT scan can help in staging the primary cancer, in choosing the best side for
biopsy, in evaluating the treatment response, in searching other synchronous tumors, in
suspect recurrence of tumor with markers increasing, and in planning radiation treatment. We
must remember that increased FDG uptake is not specific for neoplasm but inflammatory
processes may also show increased uptake, so that abscesses, tuberculosis, inflammations,
fungal infections, inflammation related to radiation treatment can concentrate radioglucose,
causing false positive results [33].
Evaluation of PET images can be performed visually or semiquantitatively, using the Stand‐
ardized Uptake Value (SUV). Semiquantitative evaluation offers a more objective way of
reporting lesion than visual image interpretation and is useful for comparing lesion activity
in consecutive studies. However, visual interpretation is equally effective for one-time
diagnosis [33].
8. PET-CT and anal cancer
Since 2005, the use of PET-CT in anal cancer has been described [34-54]. As suggested by
Grigsby et al., the advantage of FDG-PET/CT is that it can address all three staging criteria of
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the TNM system in a single whole-body imaging procedure: demonstrate the extent of the
primary tumor; detect lymph node metastases; and reveal any sites of distant metastases [55].
The 2007 National Comprehensive Cancer Network treatment guidelines included PET/CT as
a part of the standard pre-treatment workup of patients diagnosed with anal carcinoma [56].
The new version 2.2012 consider PET-CT scan for work up, even if its use for staging or
treatment planning has not been validated [57]. The Authors suggest that PET-CT actually
does not replace a diagnostic CT scan [57].
9. Detection of primary neoplam
Evidence from published data indicates that PET/CT is clearly superior to CT in visualizing
the biopsy-proven primary tumor, although the lack of sensitivity did not affect treatment.
Analyzing the Literature PET-CT detected the primary anal tumor in 59-100% of cases, while
CT scan only in 47-75%. In almost all large series are included some patients, who previously
were submitted to surgical removal of the anal cancer but with histologically confirmed
positive surgical margins. In these cases PET-CT resulted negative (false negative). When we
exclude these patients by the review, the percentage of the detection of the primary neoplasm
with PET-CT arises to 87.5-100% of cases. This suggests that both PET/CT and CT were unable
to detect residual tumor after surgical excision.
Results are repoted in Table 1 [34-54]. Figures 1 and 2 present two cases of PET-CT positive
for anal cancer.
Author, year Patients
(Total)
Detection Previous
surgery
Excluding previous
surgery
Detection CT
scan
Trautmann, 2005 21 21/21 (100%) 0 21/21 (100%) n.r.
Cotter, 2006 41 31/41 (75.6%) 7 31/34 (91%) 20/34 (59%)
Piperkova, 2006 1 1/1 (100%) 0 1/1 (100%) 1/1 (100%)
Anderson, 2007 3 3/3 (100%) 0 3/3 (100%) n.r.
Joon, 2007* 48 40/48 (83.3%) 7 40/41 (97.5%) 24/41 (58.5%)
Schwarz, 2008 53 n.r. n.r. n.r. n.r.
Nguyen, 2008* 48 40/48 (83.3%) 7 40/41 (97.5%) 22/38 (58%)
Iagaru, 2009 8 7/8 (87.5%) 0 7/8 (87.5%) n.r.
de Winton, 2009 61 45/61 (73.7%) 16 45/45 (100%) n.r.
Forrest, 2009 39 38/39 (97%) 0 38/39 (97%) 22/39 (56%)
Renaud, 2009 20 20/20 (100%) n.r. 20/20 (100%) n.r.
Kidd, 2010 77 n.r. n.r. n.r. n.r.
Krengli, 2010 27 26/27 (96.3%) n.r. 26/27 n.r.
Bannas, 2010 22 15/17 (88%) n.r. 15/17 (88%) 8/22 (47%)
Engledow, 2010 40 40/40 (100%) n.r. 40/40 (100%) n.r.
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Author, year Patients
(Total)
Detection Previous
surgery
Excluding previous
surgery
Detection CT
scan
Vercellino, 2011 22 13/22 (59%) 8 13/14 (92.8%) n.r.
Sveistrup, 2012 91 89/91 (97%) 4 87/87 (100%) n.r.
Mistrangelo, 2012 53 47/53 (88.7%) 5 47/48 (97.9%) 30/40 (75%)
Wells, 2012 30 28/30 (93%) 2 28/28 (100%) n.r.
Bhuva, 2012 43 40/43 (93%) n.r. n.r. n.r.
PS: * The 2 papers were published separately considering the same series.
n.r.: Not Reported
Table 1. Detection of primary neoplasm.
Figure 1. PET-CT positive for anal cancer.
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Figure 2. PET-CT positive for anal cancer.
10. Detection of perirectal and pelvic nodes
Perirectal and/or pelvic nodes were revealed by PET-CT in 4.5-67% and by CT-scan in 13.6-49%
of patients. In all the reported series, except the one of Bannas and Coll [47], PET-CT eviden‐
tiated more perirectal and pelvic nodes vs CT-scan
Results are repoted in Table 2 [34-54]. Figure 3 present a case of PET-CT positive for perirectal
lymph nodes metastases.
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Author, year Patients
(Total)
Incidence PET-CT Incidence CT scan
Trautmann, 2005 21 9/21 (42.8%) n.r.
Cotter, 2006 41 9/41 (22%) 8/41 (20%)
Piperkova, 2006 1 1/1 (100%) n.r.
Anderson, 2007 3 1/3 (33.3%) n.r.
Schwarz, 2008 53 n.r. n.r.
Nguyen, 2008 48 9/48 (19%) 7/38 (18%)
Iagaru, 2009 8 2/8 (20%) n.r.
de Winton, 2009 61 41/61 (67%) 30/61 (49%).
Forrest, 2009 39 n.r. n.r.
Renaud, 2009 20 12/20 (60%) n.r.
Kidd, 2010 77 8/77 (10.4%) n.r.
Krengli, 2010 27 n.r. n.r.
Bannas, 2010 22 2/17 (11.7%) 3/22 (13.6%)
Engledow, 2010 40 n.r. n.r.
Vercellino, 2011 22 1/22 (4.5%) n.r.
Sveistrup, 2012 91 28/91 (30.7%) n.r.
Mistrangelo, 2012 53 14/53 (26.4%) 7/40 (17.5%)
Wells, 2012 30 n.r. n.r.
Bhuva, 2012 43 n.r. n.r.
n.r.: Not Reported
Table 2. Incidence of perirectal and pelvic metastases in lymph nodes
11. Detection of inguinal lymph nodes
PET/CT was positive for inguinal metastases in 0-37% of patients, while CT scan in 7.4-41% of
them. Mistrangelo et Al [49] compared PET-CT with sentinel lymph node biopsy (SNB) of
inguinal nodes in 41 cases. Their findings showed that SNB confirmed the presence of inguinal
metastases in only 8 cases, with 4 of 41 patients (9.7%) false positive and 2 of 41 patients (4.9%)
false negative. Comparison between SNB and CT findings (34 patients) showed that SNB
identified 4 of 34 patients (11.7%) false positive and 4 of 34 patients (11.7%) false negative
patients. This is the only paper, to our knowledge, that compares the 2 techniques.
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Figure 3. PET-CT positive for perirectal lymph nodes metastases.
Cotter and colleagues compared CT and physical examination to 18F-FDG PET/CT in the
staging of carcinoma of anal canal, particularly of the inguinal nodal involvement [35]. They
enrolled 41 consecutive patients with biopsy proved anal cancer and studied them with
physical examination, CT scan and PET-CT scan. PET-CT scans described nodal groin
positivities in 15 patients (37%); CT documented abnormal nodes in 9 subjects (22%). Partic‐
ularly, 20% of CT-negative groins were PET positive, leading to upstaging in 8 of the 32 patients
(25%). Furthermore, 3 of 13 CT-positive groins were PET-negative (23%) [35]. About 23% of
clinically negative groins were PET-positive, leading to upstaging in 9 of the 32 subjects
without clinical inguinal nodal involvement. Moreover, about 17% of inguinal stations
negative by both CT and physical exam were PET-positive, allowing for upstaging in each of
PET-CT in Anal Cancer: Indications and Limits
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these cases. Ten of 18 inguinal stations (56%) positive by either physical examination or CT,
but not both, were positive by PET. Moreover, all four groins positive by both CT and physical
examination were positive by PET [35]. Autors concluded that PET-CT documented more
abnormal inguinal nodes than CT or physical examination and they explained that cancer
nodal metastases occur in node <5 mm in size, below the limit of detection by CT or physical
exam; instead, FDG-PET scan detects pathological sites by differential glucose intake rather
than limph node morphology; so that, PET is able in detecting little nodal metastases, but no
micrometastases.
Results are repoted in Table 3 [34-54]. Figures 4 and 5 present a case of PET-CT positive for
inguinal lymph nodes metastases.
Author, year Patients
(Total)
Incidence PET-CT Incidence CT scan
Trautmann, 2005 21 0/21 (0%) n.r.
Cotter, 2006 41 15/41 (37%) 9/41 (22%)
Piperkova, 2006 1 0/1 (0%) n.r.
Anderson, 2007 3 0/3 (0%) n.r.
Joon, 2007* 48 n.r. n.r.
Schwarz, 2008 53 n.r. n.r.
Nguyen, 2008* 48 8/48 (16.6%) n.r.
Iagaru, 2009 8 1/8 (12.5%) n.r.
de Winton, 2009 61 6/61 (10%) 9/61 (15%).
Forrest, 2009 39 n.r. n.r.
Renaud, 2009 20 5/20 (25%) 4/20 (20%)
Kidd, 2010 77 6/77 (7.8%) n.r.
Krengli, 2010 27 3/27 (11.1%) 2/27 (7.4%)
Bannas, 2010 22 6/22 (27%) 9/22 (41%)
Engledow, 2010 40 9/40 (22.5%) 0/40 (0%)
Vercellino, 2011 22 3/22 (13.6%) n.r.
Sveistrup, 2012 91 41/91 (45%) n.r.
Mistrangelo, 2012 53 12/53 (22.6%) 8/40 (20%)
Wells, 2012 30 n.r. n.r.
Bhuva, 2012 43 7/43 (16.3%) n.r.
PS: * The 2 papers were published separately considering the same series.
n.r.: Not Reported
Table 3. Incidence of metastases in inguinal lymph nodes
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Figure 4. PET-CT positive for inguinal lymph nodes metastases.
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Figure 5. PET-CT positive for inguinal lymph nodes metastases.
12. Pre-treatment final staging
In the published series tumors were staged according to the American Joint Committee on
Cancer staging system [22]. PET/CT upstaged 9-100% and dowstaged 0-25% of patients
studied. The radiation fields changed in 3.7-33.3% of cases.
Results are repoted in Table 4 [34-54].
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Author, year Patients(Total) Upstaging Downstaging Invariate Change RT planes
Trautmann, 2005 21 10% n.r. 90% n.r.
Cotter, 2006 41 17% n.r. 83% n.r.
Piperkova, 2006 1 100% 0 0 n.r.
Anderson, 2007 3 33.3% n.r. 66.6% 33.3%
Joon, 2007* 48 17% 6% 77% 19%
Schwarz, 2008 53 n.r. n.r. n.r. n.r.
Nguyen, 2008* 48 17% 6% 77% 19%
Iagaru, 2009 8 n.r. n.r. n.r. n.r.
de Winton, 2009 61 15% 8% 77% 13%
Forrest, 2009 39 n.r. n.r. n.r. n.r.
Renaud, 2009 20 15% n.r. 85% n.r.
Kidd, 2010 77 n.r. n.r. n.r. n.r.
Krengli, 2010 27 18.5% 0% 81.5% 3.7%
Bannas, 2010 22 9% 18% 73% 23%
Engledow, 2010 40 n.r. n.r. n.r. 12.5%
Vercellino, 2011 22 n.r. n.r. n.r. 20%
Sveistrup, 2012 91 14% n.r. 86% 17%
Mistrangelo, 2012 53 37.5% 25% 37.5% 12.6%
Wells, 2012 30 17% 19% 65% 29%
Bhuva, 2012 43 30.2% 11.6% 58.2% n.r.
PS: * The 2 papers were published separately considering the same series.
n.r.: Not Reported
Table 4. Upstaging and downstaging of PET-CT respect CT scan
Author, year Patients(Total) Recurrences at PET-CT FP FN
Trautmann, 2005 21 12/18 (66.6%) 9/12 (75%) 2/6 (33.3%)
Mistrangelo, 2012 53 10/43 (23.2%) 6/10 (60%) 0/33 (0%)
Table 5. Follow up at 1 month
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Author, year Patients(Total) Recurrences at PET-CT FP FN
Schwarz, 2008 53 9/53 (17%) 2/9 (22.2%) n.r.
Nguyen, 2008 48 5/25 (20%) 3/5 (60%) n.r.
Iagaru, 2009 8 1/6 (16.6%). n.r. n.r.
Forrest, 2009 39 13/39 (33.3%) 4/13 (30.7%) n.r.
Renaud, 2009 20 6/11 (54.5%) 2/6 (33.3%) 0/5 (0%)
Kidd, 2010 77 14/59 (14%) n.r. n.r.
Vercellino, 2011 22 18/36 (50%) 4/18 (22.2%) 1/18 (5.5%)
Mistrangelo, 2012 53 8/40 (4.6%) 5/8 (62.5%) 0/32 (0%)
n.r.: Not Reported
Table 6. Follow up at 3 months
12.1. Follow-up
Few papers report the results of follow up in patients submitted to combined radiochemo‐
therapy for anal cancer with PET-CT. Moreover PET-CTs of follow up were scheduled
differently. This aspect does not permit an adequate comparison between various series.
12.2. Follow-up at 1 month
Only two papers reported the results of follow up with PET/CT performed 1 month after the
end of combined radiochemotherapy [34, 49]. Recurrences are reported respectively in 66.6
and 23.2% of cases. When follow up is analyzed Trautmann [34] reported 75% of false positive
(FP) and 33.3% of false negative (FN), while Mistrangelo [49] revealed 60% of FP and none FN.
The follow up period was over 18 months in the first study, and 20.3 months in the other one.
Mistrangelo et Al compared also the results of PET-CT with anal biopsy: in the detection of
persistence of disease, PET/CT had a sensitivity of 66.6%, a specificity of 92.5%, a positive
predictive value (PPV) of 40% and a negative predictive value (NPV) of 97.4%, while anal
biopsy had a sensitivity of 100%, a specificity of 97.5%, a PPV of 75% and a NPV of 100% [49].
12.3. Follow-up at 3 months
The value of PET-CT performed 3 months after combined radiochemotherapy for anal cancer
was analyzed in only 8 papers. Recurrences were reported in 4.6-54.5% of cases [39-41, 43-45,
49-50]. False positive were reported in 22.2-62.5%, while FN in 0-5.5% of cases.
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Mistrangelo  et  Al  compared  results  with  anal  biopsy:  in  the  detection  of  recurrence  of
disease, PET/CT had a sensitivity of 100%, a specificity of 97.4%, a PPV of 66% and a NPV
of 100%. Anal biopsy had a sensitivity of 100%, a specificity of 100%, a PPV of 100% and
a NPV of 100% [49].
13. Discussion
Anal cancer is a relatively uncommon tumor, but its incidence increased over the last decades.
Accurate clinical staging is important for prognostic information, for planning the radiother‐
apy target volume and for defining therapeutic dose. An accurate evaluation of disease extent
can help to individualized radiotherapy planning, ensuring the accurate coverage of disease
and sparing of organs at risk. If inguinal node metastasis are known, the radiation plan must
include a radiation boost to the groin, but these increased radiation doses are associated with
acute and late toxicity, like chronic lymph oedema and femoral neck fracture [47].
Since 2005, the use of PET/CT in anal cancer has been described [34-55], but a medline research
about the use of PET/CT and anal cancer management shows a relatively little amount of
studies. As suggested by Grigsby et al., the advantage of FDG-PET/CT is that it can address
all three staging criteria of the TNM system in a single whole-body imaging procedure:
demonstrate the extent of the primary tumor, detect lymph node metastases, and reveal any
sites of distant metastases [55]. The 2007 National Comprehensive Cancer Network treatment
guidelines included PET/CT as a part of the standard pre-treatment workup of patients
diagnosed with anal carcinoma [56]. The new version 2.2012 consider PET-CT scan for work
up, even if its use for staging or treatment planning has not been validated [57]. The Authors
suggest that PET-CT actually does not replace a diagnostic CT scan [57].
Otherwise accurate staging of anal cancer followed by optimal planning of combined radio‐
chemotherapy treatment can extend patient survival. Anatomical imaging techniques such as
CT and MRI cannot evaluate tumor biology and behavior. PET/CT imaging is increasingly
used to stage different malignant diseases [59]. The advantage of PET/CT fusion imaging
resides in its ability to correlate findings from anatomic and functional imaging modalities,
lending it a more important role than diagnostic CT alone in the selection of proper treatment
[36]. Moreover, therapy-induced changes in tumors are related to changes in 18F-FDG uptake,
and treatment response can be efficiently monitored by PET/CT also considering the standar‐
dized uptake value (SUV) of 18F-FDG.
Evidence from published data and our study [41] indicates that PET/CT is clearly superior to
CT in visualizing the biopsy-proven primary tumor (87.5-100% vs 47-75%), although the lack
of sensitivity did not affect treatment. Otherwise both PET/CT and CT were unable to detect
residual tumor after surgical excision.
Considering the results of staging anal cancer with PET-CT respect other classical staging tools,
pre-treatment PET/CT upstaged 9-37.5% and downstaged 0-25% of patients with anal cancer
PET-CT in Anal Cancer: Indications and Limits
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[34-54]. PET/CT at diagnosis can also be used for radiation therapy treatment planning as it
clearly defines sites of metabolically active tumor [47].
Radiation treatment fields changed in 3.7-33.3% of patients [37-38, 40, 42, 46-52]. Only Vercel‐
lino et al. [50] reported no change in treatment fields in their series of 44 patients.
In the majority of studies, upstaging was related to a suggested better staging of metastases in
perirectal, pelvic and inguinal lymph nodes. As it defines nodal and metastatic disease, PET
imaging can improve the staging of anal cancer [40].
Mai and Coll assumed that PET positive lymph nodes in a setting of anal cancer as defined by
SUV uptake raise the likelihood of lymph node involvement, which would warrant more
aggressive treatment in patients with PET positive nodes [60].
The sensitivity of CT for detecting nodal metastases in the pelvic and inguinal region is limited
to 40-68% [25]. By contrast, PET/CT showed a higher specificity (80-90%) and sensitivity
(70-90%) in the detection of nodal and distant metastases for several tumor types like non-
small-cell lung cancer and head and neck cancer [25]. Also in gynecologic cancer, PET can have
a specificity of 90-95%.
Cotter et al. [35] reported that PET/CT upstages inguinal nodes in 17% of patients. They
also found a higher rate of  PET/CT positive for inguinal  metastases in HIV-seropositive
versus  HIV-seronegative  patients  (44%  vs.  16%),  while  other  Authors  observed  only  a
marginal difference in positive inguinal metastases between these two patient subgroups
(28.5% vs. 25%) [49].
Otherwise some 5% of inguinal lymph node metastases detected with PET/CT are FP at fine-
needle aspiration cytology (FNAC) [48] and up to 57% at histological confirmation of samples
from sentinel node biopsy (SNB) [61]. Iagaru [41] and Engledow [48] reported that inguinal
lymph nodes positive at PET/CT were negative at FNAC in 50% and at SNB in 5% of cases.
Therefore, positive lymph nodes identified by PET/CT should be adequately studied with
biopsy before changing radiotherapy plans. In this connection, the high incidence of inguinal
metastases found on imaging as compared with conventional staging tools should warn
against unnecessary inguinal radiotherapy. Inguinal staging with SNB may explain the lower
percentage of change in radiotherapy fields in ours series compared to others.
PET/CT was recently considered also for follow-up of patients undergoing radio- and chemo‐
therapy treatment in anal cancer. Kidd et al. [45] reported that a higher SUVmax was associated
with lymph node involvement at diagnosis. These patients were also at higher risk of persistent
disease on their post-treatment PET, if the study was performed less than 4 months after
completing therapy. The authors go on to suggest that SUVmax for FDG represents a potential
new biomarker for anal cancer prognosis, as it is significantly associated with lymph node
involvement at diagnosis, treatment response, and disease-free survival [45].
Post-treatment PET/CT is indicated to determine response to therapy and it is highly predictive
of long-term clinical outcomes [55]. It can also be used to evaluate sites of recurrent disease.
Few studies have examined clinical response to therapy, and clinical workup differs widely.
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Piperkova et al. suggested that PET/CT in anal cancer accurately identifies treatment response
[36]. Schwarz et al. [39] reported that posttherapy FDG response was the most significant
predictor of progression-free survival (P=0.0003) and that it was more predictive of the
treatment outcome than either pre-treatment tumor size (P=0.08) or nodal status (P=0.40).
Persistent disease is indeed a predictor of poor clinical outcome [39].
Mistrangelo et Al [49] reported that PET/CT assessment at 1 month had a sensitivity of 66.6%,
a specificity of 92.5%, a PPV of 40% and a NPV of 97.4% for detecting persistence of anal disease.
These data are not comparable to previous observations. Only Trautmann et al. [34] reported
on the results of PET/CT assessment at 1 month (persistence of disease of 66.6% of cases),
suggesting that PET/CT at 1 month after the end of therapy is of little value in predicting the
durability of response.
In contrast, anal biopsy at 1-month follow-up had higher sensitivity and specificity than PET/
CT, even if assessment with biopsy of non-progressive residual tumor at 1 month after
treatment may be misleading as shortly after radiation nonviable cancer cell may look
morphologically intact [62].
Considering these aspects biopsy for a non-progressive residual tumor at 1 month after
treatment shoud not be taken as this can lead to unnecessary abdominoperineal excision. These
patients should be closely observed.
Mistrangelo et Al reported that PET/CT assessment at 3 months had a sensitivity of 100%, a
specificity of 97.4%, a PPV of 66% and a NPV of 100%; anal biopsy had the same sensitivity
but a better specificity than PET/CT [49]. Vercellino and Coll [50] reported thet sensitivity,
specificity and negative predictive value of PET-CT for the detection of recurrent locoregional
disease is 93%, 81% and 94% respectively, resulting in an impact on management in 20%.
14. Conclusions
The role of PET-CT in the evaluation of anal cancer is evolving. PET/CT detect the primary
tumor more often than CT, but neither tool is indicated to reveal persistent disease after
surgery. PET/CT proved useful in initial staging perirectal/pelvic or inguinal lymph nodes.
PET/CT can document also unknown metastases, changing the disease stadiation. However,
upstaging related to lymph nodes metastases might have been overestimated, as up to 31% of
inguinal metastases identified by PET/CT are reportedly false positive, but metabolic imaging
can descover little nodal metastases, too little for CT and clinical evaluation. Currently,
inguinal lymph nodes are better staged by sentinel node biopsy. PET/CT assessment at 1-
month follow-up had lower sensitivity and specificity than anal biopsy.
PET/CT assessment at 3 months more accurately evaluated the persistence or the recurrence
of anal disease and thus allowed for better follow up when combined with anal biopsy.
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